Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis

Ann Rheum Dis. 2021 Apr;80(4):543-545. doi: 10.1136/annrheumdis-2020-218582. Epub 2020 Oct 28.

Authors

Yuchuan Ding¹, Baozhen Huang², Yuan Wang¹, Jun Hou¹, Ying Chi¹, Zhixuan Zhou¹, Jianguo Li³

Affiliations

¹ Department of Rheumatology and Immunology, Capital Institute of Pediatrics, Beijing, China.
² Department of Chemical Pathology, The Chinese University of Hong Kong Faculty of Medicine, Pokfulam, Hong Kong.
³ Department of Rheumatology and Immunology, Capital Institute of Pediatrics, Beijing, China jianguo_li6@hotmail.com.

No abstract available

Keywords: dermatomyositis; glucocorticoids; inflammation.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Dermatomyositis* / drug therapy
Exanthema* / etiology
Humans
Janus Kinase Inhibitors* / therapeutic use
Muscle Strength

Substances

Janus Kinase Inhibitors